Here, we have implemented a gene therapy strategy to enhance GCase activity in mice and nonhuman primate (NHP) models of PD-like synucleinopathy by taking advantage of the intraparenchymal focused delivery into the substantia nigra pars compacta (SNpc) of rAAVs coding for the GBA1 gene. Here, GBA1 is linked to Parkinson disease.